Skip to content
2000
Volume 21, Issue 1
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Objective

The study aimed to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.

Methods

We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG; n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG; n=40, treated solely with targeted therapy).

Results

The Overall Response Rate (ORR) and Disease Control Rate (DCR) in the OG group (70.00%, 95.00%) were significantly higher than those in the CG group (57.50%, 87.50%). After 6 weeks of treatment, the OG group had significantly lower levels of SCC, CEA, and CA125, higher CD4+ levels, and lower CD8+ levels, compared to the CG group. The 24-month follow-up survival rate of the OG group (47.50%) was significantly higher than that of the CG group (27.50%).

Conclusion

CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.

© 2025 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056311827241211092432
2025-01-02
2025-10-28

  • From This Site

    /content/journals/cmir/10.2174/0115734056311827241211092432
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmir/21/1/CMIR-21-E15734056311827.html?itemId=/content/journals/cmir/10.2174/0115734056311827241211092432&mimeType=html&fmt=ahah

References

  1. AhmedT. VialM.R. OstD. StewartJ. HasanM.A. GrosuH.B. Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series.Lung Cancer201812222022310.1016/j.lungcan.2018.06.02430032836
     [Google Scholar]
  2. RAFEiH. El-BaheshE. FiNiANOSA.N.T.O.I.N.E. NASSEREDDiNES.A.M.A.H. TabbaraI. Immune-based therapies for non-small cell lung cancer.Anticancer Res.201737237738810.21873/anticanres.1133028179283
     [Google Scholar]
  3. ArrietaO. BarrónZ.Z.L. CardonaA.F. CarmonaA. MejiaL.M. Ramucirumab in the treatment of non-small cell lung cancer.Expert Opin. Drug Saf.201716563764410.1080/14740338.2017.131322628395526
     [Google Scholar]
  4. GinnL. ShiL. La MontagnaM. GarofaloM. LncRNAs in non-small-cell lung cancer.Noncoding RNA2020632510.3390/ncrna603002532629922
     [Google Scholar]
  5. WangX. ZhangG. ChengZ. DaiL. JiaL. JingX. WangH. ZhangR. LiuM. JiangT. YangY. YangM. Knockdown of LncRNA-XIST suppresses proliferation and TGF-β1-induced EMT in NSCLC through the Notch-1 pathway by regulation of miR-137.Genet. Test. Mol. Biomarkers201822633334210.1089/gtmb.2018.002629812958
     [Google Scholar]
  6. ChenP. LiuY. WenY. ZhouC. Non‐small cell lung cancer in China.Cancer Commun.2022421093797010.1002/cac2.1235936075878
     [Google Scholar]
  7. RathB. PlanggerA. HamiltonG. Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer.Cancer Drug Resist.20203217117810.20517/cdr.2019.8535582610
     [Google Scholar]
  8. SchabathM.B. CoteM.L. Cancer progress and priorities: Lung cancer.Cancer Epidemiol. Biomarkers Prev.201928101563157910.1158/1055‑9965.EPI‑19‑022131575553
     [Google Scholar]
  9. RomaszkoA.M. DoboszyńskaA. Multiple primary lung cancer: A literature review.Adv. Clin. Exp. Med.201827572573010.17219/acem/6863129790681
     [Google Scholar]
  10. JonesG.S. BaldwinD.R. Recent advances in the management of lung cancer.Clin. Med.2018182s41s4610.7861/clinmedicine.18‑2‑s4129700092
     [Google Scholar]
  11. NooreldeenR. BachH. Current and future development in lung cancer diagnosis.Int. J. Mol. Sci.20212216866110.3390/ijms2216866134445366
     [Google Scholar]
  12. TanA.C. Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC).Thorac. Cancer202011351151810.1111/1759‑7714.1332831989769
     [Google Scholar]
  13. GoldingB. LuuA. JonesR. PetitV.A.M. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).Mol. Cancer20181715210.1186/s12943‑018‑0810‑429455675
     [Google Scholar]
  14. ZhangK.R. ZhangY.F. LeiH.M. TangY.B. MaC.S. LvQ.M. WangS.Y. LuL.M. ShenY. ChenH.Z. ZhuL. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer.Sci. Transl. Med.202113614eabg642810.1126/scitranslmed.abg642834613810
     [Google Scholar]
  15. ChockalingamA. KonstantinidisM. KooB. MoonJ.T. TranA. NourouzpourS. LawsonE. FoxK. HabibollahiP. OdisioB. LoyaM. BassirA. NezamiN. Surgical resection, radiotherapy and percutaneous thermal ablation for treatment of stage 1 non-small cell lung cancer: Protocol for a systematic review and network meta-analysis.BMJ Open2022126e05763810.1136/bmjopen‑2021‑05763835710245
     [Google Scholar]
  16. RangamuwaK. LeongT. WeedenC. LabatA.M.L. BozinovskiS. ChristieM. JohnT. AntippaP. IrvingL. SteinfortD. Thermal ablation in non-small cell lung cancer: A review of treatment modalities and the evidence for combination with immune checkpoint inhibitors.Transl. Lung Cancer Res.20211062842285710.21037/tlcr‑20‑107534295682
     [Google Scholar]
  17. LiJ. ZhongX. ZhaoY. ShenJ. PilapongC. XiaoZ. Polyphenols as lung cancer chemopreventive agents by targeting microRNAs.Molecules20222718590310.3390/molecules2718590336144639
     [Google Scholar]
  18. DrostenM. BarbacidM. Targeting KRAS mutant lung cancer: Light at the end of the tunnel.Mol. Oncol.20221651057107110.1002/1878‑0261.1316834951114
     [Google Scholar]
  19. ErnaniV. StinchcombeT.E. Management of brain metastases in non–small-cell lung cancer.J. Oncol. Pract.2019151156357010.1200/JOP.19.0035731715122
     [Google Scholar]
  20. YeX. WeiZ. YangX. Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation.J. Cancer Res. Ther.20201651191119510.4103/jcrt.JCRT_798_2033004770
     [Google Scholar]
  21. MillerL.J. DouglasC. McCulloughF.S. StanworthS.J. CalderP.C. Impact of enteral immunonutrition on infectious complications and immune and inflammatory markers in cancer patients undergoing chemotherapy: A systematic review of randomised controlled trials.Clin. Nutr.202241102135214610.1016/j.clnu.2022.07.03936067585
     [Google Scholar]
  22. HattoriS. OkauchiS. SasataniY. OharaG. MiyazakiK. SatoS. KodamaT. ShiozawaT. SatohH. HizawaN. Discontinuation of immune checkpoint inhibitor and survival in patients with non-small-cell lung cancer without a driver gene mutation.Anticancer Res.20224294589459510.21873/anticanres.1596236039463
     [Google Scholar]
/content/journals/cmir/10.2174/0115734056311827241211092432
Loading
A Comparative Study on CT-guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients
Curr. Med. Imaging 21, E15734056311827 (2025); https://doi.org/10.2174/0115734056311827241211092432
/content/journals/cmir/10.2174/0115734056311827241211092432
/content/journals/cmir/10.2174/0115734056311827241211092432
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Clinical efficacy; Immune response; Lung cancer; Radiofrequency ablation; Safety; Survival time; Targeted therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test